Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lemonex Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, both of whom are located within 1 distinct art unit. This suggests that the company's pharmaceutical innovations are being reviewed within a single specialized technical silo.
The busiest examiner for this portfolio is SONG, JIANFENG, who is managing 1 pending office action. Because there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for exactly 1 matter. This distribution ensures that the prosecution of each application is handled independently by different personnel within the same unit.
The presence of 1 distinct art unit implies that the technical standards and prior art references used for both applications are likely to be similar. Practitioners should coordinate their strategies to ensure that arguments made to the 2 distinct examiners remain consistent. With 2 pending office actions, the portfolio is currently small but requires precise management within its 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| HARTLEY, MICHAEL G | 1 | 38.0% | +74.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17264944 | POLYPEPTIDE DELIVERY COMPOSITION | HARTLEY, MICHAEL G | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17264944 | POLYPEPTIDE DELIVERY COMPOSITION | HARTLEY, MICHAEL G | 34d |
| 18910379 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | SONG, JIANFENG | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18910379 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | SONG, JIANFENG | — | §102§103DP | Non-Final OA | — | Pending | Oct 09, 2024 |
| 17264944 | POLYPEPTIDE DELIVERY COMPOSITION | HARTLEY, MICHAEL G | 1618 | §103§112 | Non-Final OA | 34d | Pending | Feb 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial